Lamorde, MohammedByakika-Kibwika, PaulineOkaba-Kayom, VioletRyan, MairinCoakley, PeterBoffito, MartaNamakula, RhodaKalemeera, FrancisColebunders, RobertBack, DavidKhoo, SayeMerry, Concepta2022-01-122022-01-122011Lamorde, M., Byakika-Kibwika, P., Okaba-Kayom, V., Ryan, M., Coakley, P., Boffito, M., ... & Merry, C. (2011). Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin. Journal of Antimicrobial Chemotherapy, 66(1), 180-183. doi:10.1093/jac/dkq41110.1093/jac/dkq411https://nru.uncst.go.ug/xmlui/handle/123456789/1227In resource-poor countries, HIV and tuberculosis (TB) co-infection results in significant morbidity and mortality. Co-treatment is recommended by the WHO;1 however, drug interactions are common between anti-TB regimens containing rifampicin and antiretroviral drugs. In these settings, rifampicin is a key drug for TB treatment because alternative rifamycins are more expensive and usually not available in public TB control programmes. Similarly, for HIV treatment, only a limited number of antiretroviral drugs are routinely used. The problems arising from limited drug options are compounded by the wide use of fixed-dose combination (FDC) formulations for both diseases. When these formulations are used, drug substitutions are not possible and dose adjustments are usually difficult.enPKAntimycobacterial agentsHIV antiviral pharmacologyArticle